Bayer HealthCare will invest $100 million in its Berkeley, CA manufacturing site to build a product testing facility that will support the next generation of treatments for hemophilia A.
 
“Building upon our legacy in hemophilia A, we are delighted to continue Bayer’s leadership in working to bring treatment options to patients around the world,” said Joerg Heidrich, senior vice president for Product Supply Biotech and site head at Bayer Berkeley.
 
“The new product testing facility will test Bayer’s investigational products in accordance with rigorous global regulatory requirements,” said David Weinreich, MD, head, Global Development, Specialty Medicine at Bayer. “With today’s announcement, we are thrilled to further strengthen our commitment to the hemophilia A patient community that Bayer has served for more than a quarter century.”